ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Purpose
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complete response (pCR) after preoperative (neoadjuvant) chemotherapy with trastuzumab. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called HER2. HER2 is found on some cancer cells. When trastuzumab or pertuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving 6 months of HER2-targeted therapy may work better than giving 12 months for the treatment of HER2+ breast cancer in patients that had a pCR after neoadjuvant chemotherapy with trastuzumab.
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage II Breast Cancer AJCC v8
- Early Stage Breast Carcinoma
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Patients (females and males) with clinical stage T1c-T3 (or Tx) and nodal stage N0-N1 (except T3N1 tumors, which are not eligible) - Patients must have no residual invasive disease in the breast or lymph nodes after the completion of neoadjuvant therapy. Residual ductal carcinoma in situ (DCIS) is allowed. Patients with residual isolated tumor cells at surgery are considered node-positive and are not eligible - HER2+ by American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines. Central pathology review is not required. In cases where there were multiple tumor sites in breast/nodes that had HER2 testing at diagnosis, at least one site must have been HER2+ AND the treating investigator must feel it is in the patient's best interest to be treated as having HER2+ breast cancer - Known hormone receptor status as defined by ASCO/CAP guidelines. Estrogen receptor (ER) and progesterone receptor (PR) of any values are allowed. Hormone receptor positive status can be determined by either known positive ER or known positive PR status; hormone receptor negative status must be determined by both known negative ER and known negative PR - If invasive disease was present in both breasts, participation in the study is permitted as long as the eligibility criteria are met for both tumors/breasts (including the requirement that at least one biopsied site on each side must have been HER2+) - Age ≥ 18 years - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 - Patients must have received neoadjuvant chemotherapy in combination with trastuzumab with or without pertuzumab for a minimum of 12 weeks. All chemotherapy must have been completed preoperatively - Patient must complete a minimum of 12 weeks of coverage with trastuzumab and a maximum of 24 weeks in the combined neoadjuvant and adjuvant setting prior to trial registration. Trastuzumab may have been administered either weekly or once every 3 weeks (q3weeks). (For purposes of this eligibility criterion, a single dose of q3week trastuzumab would provide 3 weeks of coverage; a single dose of once a week (q1week) trastuzumab would provide 1 week of coverage. If a q3week dose of trastuzumab were administered and then the subsequent dose was delayed for any period of time, that would still count as 3 weeks of coverage.) - Administration of endocrine therapy for treatment of this breast cancer is allowed prior to trial registration. If a patient received prior breast cancer endocrine therapy (eg tamoxifen or aromatase inhibitor) for DCIS or preventive indication, and endocrine therapy is indicated for treatment of their current breast cancer, then prior endocrine therapy must have been stopped > 12 months prior to registration on this protocol - No use of investigational anti-cancer agents at time of registration - Patient must register within 14 weeks of final surgery - Adequate excision: Surgical removal of all clinically evident disease in the breast and lymph nodes as follows: - Breast surgery: Total mastectomy with grossly negative margins (in the opinion of the surgeon there is no disease grossly at the margins) or breast-conserving surgery with histologically negative margins (no ink on tumor, including DCIS) unless those margins are anterior at the skin or posterior at the chest wall and no additional margin re-excision can be performed - Lymph node surgery: Lymph node surgery must have been performed and can include sentinel lymph node biopsy, targeted axillary dissection, or axillary dissection, at the discretion of the breast surgeon - Adequate radiation: Patients who completed breast-conserving surgery (i.e. lumpectomy) must have received or plan to receive adjuvant radiation. If breast-conserving surgery was performed but patient will not be receiving breast radiation, the patient is not eligible. Patients for whom radiotherapy would be recommended for breast cancer treatment but for whom it is contraindicated because of medical reasons (e.g., connective tissue disorder or prior ipsilateral breast radiation) are not eligible - Adjuvant radiation can be given on study, and in this case is encouraged to be given concurrently with adjuvant HER2-directed therapy, per investigator discretion - Targeting of the regional nodal basins will be at treating investigator discretion - Not pregnant and not nursing, because this study involves agents with known teratogenic potential. Therefore, for women of childbearing potential only, a negative serum or urine pregnancy test should be performed prior to receiving HER2-directed therapy according to local standard practice - Adequate hepatic, renal and bone marrow function to receive adjuvant HER2-directed therapy in the opinion of the treating investigator. There are no specific required laboratory values for eligibility - No stage IV (metastatic) breast cancer - Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial - No history of any prior (ipsilateral [ipsi-] or contralateral) invasive breast cancer. Prior DCIS is allowed - No evidence of recurrent disease following preoperative therapy and surgery - Patients living with HIV who are healthy and deemed by their medical team to have a low risk of AIDS-related illnesses are included in this trial. Patients with Hepatitis B or Hepatitis C virus who are healthy and deemed by their medical team to meet all other enrollment criteria are included in this trial. - Patients with inadequate cardiac function on most recent assessment of left ventricular ejection fraction (LVEF) are not eligible for this trial. Inadequate cardiac function is defined as LVEF < 50% on echocardiogram (echo) or multiple-gated acquisition (MUGA) - No history of grade 3 or 4 toxicity related to trastuzumab. If pertuzumab is planned to be given on trial, patient must also have no history of grade 3-4 toxicity related to pertuzumab - No contraindication to receipt of further HER2-directed therapy - No patients with severe, uncontrolled systemic disease that may interfere with planned trial therapy.
Exclusion Criteria
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator Arm 1 (12-month adjuvant therapy) |
Patients receive trastuzumab IV or SC on day 1 of each cycle. Patients may also receive pertuzumab IV or SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA as well as mammography, ultrasound, or MRI throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial. |
|
|
Experimental Arm 2 (6-month adjuvant therapy) |
Patients receive trastuzumab IV or SC on day 1 of each cycle. Patients may also receive pertuzumab IV or SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA as well as mammography, ultrasound, or MRI throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial. |
|
Recruiting Locations
Carmichael 5334336, California 5332921 95608
Carmichael 5334336, California 5332921 95608
Chico 5336269, California 5332921 95926
Site Public Contact
530-332-4700
Dublin 5344157, California 5332921 94568
Site Public Contact
877-642-4691
Elk Grove 5346111, California 5332921 95758
Fremont 5350734, California 5332921 94538
Fresno 5350937, California 5332921 93720
Site Public Contact
833-574-2273
Irvine 5359777, California 5332921 92612
Marysville 5370984, California 5332921 95901
Site Public Contact
530-749-4400
Modesto 5373900, California 5332921 95356
Oakland 5378538, California 5332921 94611
Orange 5379513, California 5332921 92868
Rocklin 5388319, California 5332921 95765
Roseville 5388881, California 5332921 95661
Sacramento 5389489, California 5332921 95814
Sacramento 5389489, California 5332921 95816
Sacramento 5389489, California 5332921 95817
Site Public Contact
916-734-3089
Sacramento 5389489, California 5332921 95823
San Francisco 5391959, California 5332921 94115
San Jose 5392171, California 5332921 95119
San Leandro 5392263, California 5332921 94577
San Rafael 5392567, California 5332921 94903
Santa Clara 5393015, California 5332921 95051
Santa Rosa 5393287, California 5332921 95403
South San Francisco 5397765, California 5332921 94080
Truckee 5403676, California 5332921 96161
Site Public Contact
530-582-6450
Vallejo 5405380, California 5332921 94589
Walnut Creek 5406990, California 5332921 94596
Woodland 5410430, California 5332921 95695
Yorba Linda 5410902, California 5332921 92886
Edwards 5420885, Colorado 5417618 81632
Site Public Contact
970-569-7429
Derby 4832745, Connecticut 4831725 06418
Fairfield 4834157, Connecticut 4831725 06824
Glastonbury 4835003, Connecticut 4831725 06033
Greenwich 4835395, Connecticut 4831725 06830
Guilford 4835512, Connecticut 4831725 06437
Hartford 4835797, Connecticut 4831725 06105
New Haven 4839366, Connecticut 4831725 06520
North Haven 4839704, Connecticut 4831725 06473
Stamford 4843564, Connecticut 4831725 06902
Torrington 4844309, Connecticut 4831725 06790
Trumbull 4844459, Connecticut 4831725 06611
Waterbury 4845193, Connecticut 4831725 06708
Waterford 8480031, Connecticut 4831725 06385
Millville 4143696, Delaware 4142224 19967
Newark 4143861, Delaware 4142224 19713
Newark 4143861, Delaware 4142224 19713
Rehoboth Beach 4144284, Delaware 4142224 19971
Washington D.C. 4140963, District of Columbia 4138106 20007
Site Public Contact
202-444-2223
Washington D.C. 4140963, District of Columbia 4138106 20010
Site Public Contact
202-877-8839
Clearwater 4151316, Florida 4155751 33756
Site Public Contact
855-314-8646
Jupiter 4160610, Florida 4155751 33458
Pensacola 4168228, Florida 4155751 32504
Plant City 4168773, Florida 4155751 33563
St. Petersburg 4171563, Florida 4155751 33705
Tampa 4174757, Florida 4155751 33607
Winter Haven 4178552, Florida 4155751 33881
Honolulu 5856195, Hawaii 5855797 96819
Boise 5586437, Idaho 5596512 83712
Coeur d'Alene 5589173, Idaho 5596512 83814
Fruitland 5593708, Idaho 5596512 83619
Meridian 5600685, Idaho 5596512 83642
Nampa 5601933, Idaho 5596512 83687
Post Falls 5604353, Idaho 5596512 83854
Sandpoint 5606401, Idaho 5596512 83864
Bloomington 4885164, Illinois 4896861 61704
Canton 4831990, Illinois 4896861 61520
Carterville 4235311, Illinois 4896861 62918
Carthage 4886716, Illinois 4896861 62321
Centralia 4235587, Illinois 4896861 62801
Chicago 4887398, Illinois 4896861 60611
Chicago 4887398, Illinois 4896861 60637
Decatur 4236895, Illinois 4896861 62526
Decatur 4236895, Illinois 4896861 62526
Dixon 4889959, Illinois 4896861 61021
Site Public Contact
815-285-7800
Effingham 4237727, Illinois 4896861 62401
Eureka 4891310, Illinois 4896861 61530
Galesburg 4893392, Illinois 4896861 61401
Hinsdale 4896012, Illinois 4896861 60521
Kewanee 4898433, Illinois 4896861 61443
Macomb 4900817, Illinois 4896861 61455
New Lenox 4903535, Illinois 4896861 60451
O'Fallon 4245926, Illinois 4896861 62269
Orland Park 4904937, Illinois 4896861 60462
Ottawa 4905006, Illinois 4896861 61350
Pekin 4905599, Illinois 4896861 61554
Peoria 4905687, Illinois 4896861 61615
Peru 4905770, Illinois 4896861 61354
Princeton 4906818, Illinois 4896861 61356
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
800-444-7541
Springfield 4250542, Illinois 4896861 62781
Washington 4915545, Illinois 4896861 61571
Crown Point 4919451, Indiana 4921868 46307
Ames 4846834, Iowa 4862182 50010
Site Public Contact
515-956-4132
Ames 4846834, Iowa 4862182 50010
Ankeny 4846960, Iowa 4862182 50023
Site Public Contact
515-241-3305
Boone 4849051, Iowa 4862182 50036
Site Public Contact
515-956-4132
Carroll 4850478, Iowa 4862182 51401
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-365-4673
Cedar Rapids 4850751, Iowa 4862182 52403
Site Public Contact
319-363-2690
Clive 4852065, Iowa 4862182 50325
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-6727
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-282-2200
Des Moines 4853828, Iowa 4862182 50314
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-241-3305
Fort Dodge 4857486, Iowa 4862182 50501
Site Public Contact
515-956-4132
Fort Dodge 4857486, Iowa 4862182 50501
Jefferson 4862482, Iowa 4862182 50129
Site Public Contact
515-956-4132
Marshalltown 4866371, Iowa 4862182 50158
Site Public Contact
515-956-4132
Pella 4870915, Iowa 4862182 50219
Waukee 4880981, Iowa 4862182 50263
Site Public Contact
515-241-3305
West Des Moines 4881346, Iowa 4862182 50266
Site Public Contact
515-875-9815
Chanute 4269392, Kansas 4273857 66720
Dodge City 5445298, Kansas 4273857 67801
El Dorado 4270863, Kansas 4273857 67042
Independence 4273359, Kansas 4273857 67301
Kingman 4273978, Kansas 4273857 67068
Liberal 5445820, Kansas 4273857 67905
Newton 4276248, Kansas 4273857 67114
Olathe 4276614, Kansas 4273857 66061
Overland Park 4276873, Kansas 4273857 66210
Overland Park 4276873, Kansas 4273857 66211
Parsons 4277011, Kansas 4273857 67357
Pratt 4277752, Kansas 4273857 67124
Salina 4278890, Kansas 4273857 67401
Salina 4278890, Kansas 4273857 67401
Topeka 4280539, Kansas 4273857 66606
Site Public Contact
785-295-8000
Wellington 4281386, Kansas 4273857 67152
Westwood 4281639, Kansas 4273857 66205
Wichita 4281730, Kansas 4273857 67208
Wichita 4281730, Kansas 4273857 67214
Wichita 4281730, Kansas 4273857 67214
Winfield 4281897, Kansas 4273857 67156
Louisville 4299276, Kentucky 6254925 40202
Site Public Contact
502-562-3429
Louisville 4299276, Kentucky 6254925 40245
New Orleans 4335045, Louisiana 4331987 70112
New Orleans 4335045, Louisiana 4331987 70121
Brewer 4959233, Maine 4971068 04412
Site Public Contact
800-987-3005
Aberdeen 4346913, Maryland 4361885 21001
Baltimore 4347778, Maryland 4361885 21201
Site Public Contact
800-888-8823
Baltimore 4347778, Maryland 4361885 21204
Site Public Contact
443-849-3706
Baltimore 4347778, Maryland 4361885 21237
Site Public Contact
443-777-7364
Baltimore 4347778, Maryland 4361885 21239
Bel Air 4348240, Maryland 4361885 21014
Site Public Contact
443-643-3010
Cumberland 4352681, Maryland 4361885 21502
Site Public Contact
240-964-1400
Olney 4364537, Maryland 4361885 20832
Site Public Contact
855-546-1944
Battle Creek 4985153, Michigan 5001836 49017
Brighton 4986994, Michigan 5001836 48114
Canton 4987990, Michigan 5001836 48188
Chelsea 4988628, Michigan 5001836 48118
Clarkston 4988997, Michigan 5001836 48346
Clarkston 4988997, Michigan 5001836 48346
Escanaba 4992232, Michigan 5001836 49829
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Grand Rapids 4994358, Michigan 5001836 49503
Grand Rapids 4994358, Michigan 5001836 49503
Kalamazoo 4997787, Michigan 5001836 49007
Kalamazoo 4997787, Michigan 5001836 49007
Lansing 4998830, Michigan 5001836 48912
Livonia 4999837, Michigan 5001836 48154
Muskegon 5003132, Michigan 5001836 49444
Niles 5003514, Michigan 5001836 49120
Site Public Contact
616-391-1230
Norton Shores 5004005, Michigan 5001836 49444
Pontiac 5006166, Michigan 5001836 48341
Pontiac 5006166, Michigan 5001836 48341
Pontiac 5006166, Michigan 5001836 48341
Pontiac 5006166, Michigan 5001836 48341
Reed City 5006946, Michigan 5001836 49677
Saint Joseph 5008327, Michigan 5001836 49085
Saint Joseph 5008327, Michigan 5001836 49085
Traverse City 5012495, Michigan 5001836 49684
Wyoming 5015618, Michigan 5001836 49519
Ypsilanti 5015688, Michigan 5001836 48197
Bemidji 5017822, Minnesota 5037779 56601
Thief River Falls 5049970, Minnesota 5037779 56701
Site Public Contact
605-312-3320
Worthington 5053460, Minnesota 5037779 56187
Site Public Contact
605-312-3320
Ballwin 4375663, Missouri 4398678 63011
Site Public Contact
888-446-3729
Cape Girardeau 4379966, Missouri 4398678 63703
Farmington 4386289, Missouri 4398678 63640
Site Public Contact
314-996-5569
Kansas City 4393217, Missouri 4398678 64108
Site Public Contact
816-404-4375
Kansas City 4393217, Missouri 4398678 64116
Site Public Contact
913-588-3671
Kansas City 4393217, Missouri 4398678 64154
Lee's Summit 4394870, Missouri 4398678 64064
Osage Beach 4402040, Missouri 4398678 65065
Sainte Genevieve 4407294, Missouri 4398678 63670
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63131
Site Public Contact
314-996-5569
St Louis 4407066, Missouri 4398678 63141
Site Public Contact
314-251-7066
Sullivan 4410669, Missouri 4398678 63080
Site Public Contact
314-996-5569
Sunset Hills 4410836, Missouri 4398678 63127
Site Public Contact
314-996-5569
Anaconda 5637146, Montana 5667009 59711
Billings 5640350, Montana 5667009 59101
Great Falls 5655240, Montana 5667009 59405
Missoula 5666639, Montana 5667009 59804
Cherry Hill 4501198, New Jersey 5101760 08002
Sewell 4504048, New Jersey 5101760 08080
Stony Brook 5139865, New York 5128638 11794
Site Public Contact
800-862-2215
Chapel Hill 4460162, North Carolina 4482348 27599
Charlotte 4460243, North Carolina 4482348 28204
Hendersonville 4470592, North Carolina 4482348 28791
Huntersville 4472370, North Carolina 4482348 28078
Kernersville 4474221, North Carolina 4482348 27284
Matthews 4478334, North Carolina 4482348 28105
Mooresville 4480125, North Carolina 4482348 28117
Mount Airy 4480378, North Carolina 4482348 27030
Pinehurst 4485272, North Carolina 4482348 28374
Thomasville 4494942, North Carolina 4482348 27360
Winston-Salem 4499612, North Carolina 4482348 27103
Bismarck 5688025, North Dakota 5690763 58501
Fargo 5059163, North Dakota 5690763 58122
Fargo 5059163, North Dakota 5690763 58122
Canton 5149222, Ohio 5165418 44710
Cincinnati 4508722, Ohio 5165418 45219
Columbus 4509177, Ohio 5165418 43210
West Chester 4520522, Ohio 5165418 45069
Gresham 5729485, Oregon 5744337 97030
Site Public Contact
503-413-2150
Hood River 5731777, Oregon 5744337 97031
Newberg 5742726, Oregon 5744337 97132
Oregon City 5744253, Oregon 5744337 97045
Portland 5746545, Oregon 5744337 97210
Portland 5746545, Oregon 5744337 97213
Portland 5746545, Oregon 5744337 97225
Tualatin 5757506, Oregon 5744337 97062
Site Public Contact
503-413-1742
Beaver 5179446, Pennsylvania 6254927 15009
Butler 5182534, Pennsylvania 6254927 16001
Chambersburg 4557109, Pennsylvania 6254927 17201
Site Public Contact
717-217-6020
Cranberry Township 8643098, Pennsylvania 6254927 16066
Ephrata 5188815, Pennsylvania 6254927 17522
Site Public Contact
717-721-4840
Erie 5188843, Pennsylvania 6254927 16505
Farrell 5189377, Pennsylvania 6254927 16121
Gettysburg 4558183, Pennsylvania 6254927 17325
Site Public Contact
877-441-7957
Greensburg 5192029, Pennsylvania 6254927 15601
Site Public Contact
724-838-1900
Harrisburg 5192726, Pennsylvania 6254927 17109
Indiana 5194868, Pennsylvania 6254927 15701
Johnstown 5195561, Pennsylvania 6254927 15901
Site Public Contact
814-534-4724
Lebanon 5197517, Pennsylvania 6254927 17042
McKeesport 5200499, Pennsylvania 6254927 15132
Site Public Contact
412-647-8073
Mechanicsburg 5200657, Pennsylvania 6254927 17050
Monroeville 5201734, Pennsylvania 6254927 15146
N. Huntingdon, Pennsylvania 6254927 15642
New Castle 5203127, Pennsylvania 6254927 16105
Philadelphia 4560349, Pennsylvania 6254927 19107
Philadelphia 4560349, Pennsylvania 6254927 19114
Pittsburgh 5206379, Pennsylvania 6254927 15213
Site Public Contact
412-647-2811
Pittsburgh 5206379, Pennsylvania 6254927 15215
Site Public Contact
412-784-4900
Pittsburgh 5206379, Pennsylvania 6254927 15237
Site Public Contact
412-367-6454
Pittsburgh 5206379, Pennsylvania 6254927 15243
Site Public Contact
412-502-3920
Seneca 5211432, Pennsylvania 6254927 16346
Site Public Contact
814-676-7900
Uniontown 4561859, Pennsylvania 6254927 15401
Washington 5218069, Pennsylvania 6254927 15301
West Mifflin 5218802, Pennsylvania 6254927 15122
Site Public Contact
412-653-8100
Williamsport 5219585, Pennsylvania 6254927 17754
Willow Grove 5219619, Pennsylvania 6254927 19090
York 4562407, Pennsylvania 6254927 17403
Site Public Contact
717-741-9229
York 4562407, Pennsylvania 6254927 17403
Site Public Contact
877-441-7957
Westerly 5225631, Rhode Island 5224323 02891
Boiling Springs 4571805, South Carolina 4597040 29316
Easley 4577263, South Carolina 4597040 29640
Greenville 4580543, South Carolina 4597040 29605
Greenville 4580543, South Carolina 4597040 29605
Greenville 4580543, South Carolina 4597040 29615
Greer 4580599, South Carolina 4597040 29650
Seneca 4595346, South Carolina 4597040 29672
West Columbia 4600541, South Carolina 4597040 29169
Rapid City 5768233, South Dakota 5769223 57701
Sioux Falls 5231851, South Dakota 5769223 57104
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Lynchburg 4771075, Virginia 6254928 24501
Mechanicsville 4772566, Virginia 6254928 23116
Midlothian 4772943, Virginia 6254928 23114
Richmond 4781708, Virginia 6254928 23226
Richmond 4781708, Virginia 6254928 23229
Richmond 4781708, Virginia 6254928 23235
Richmond 4781708, Virginia 6254928 23298
South Hill 4786619, Virginia 6254928 23970
Vancouver 5814616, Washington 5815135 98684
Vancouver 5814616, Washington 5815135 98686
Site Public Contact
503-413-2150
Huntington 4809537, West Virginia 4826850 25701
Antigo 5244010, Wisconsin 5279468 54409
Green Bay 5254962, Wisconsin 5279468 54301
Green Bay 5254962, Wisconsin 5279468 54303
Madison 5261457, Wisconsin 5279468 53718
Madison 5261457, Wisconsin 5279468 53792
Medford 5262475, Wisconsin 5279468 54451
Menomonee Falls 5262630, Wisconsin 5279468 53051
Site Public Contact
262-257-5100
Milwaukee 5263045, Wisconsin 5279468 53226
Site Public Contact
414-805-3666
Oak Creek 5265228, Wisconsin 5279468 53154
Site Public Contact
414-805-0505
Oconto Falls 5265522, Wisconsin 5279468 54154
Rhinelander 5268720, Wisconsin 5279468 54501
Sheboygan 5272893, Wisconsin 5279468 53081
Sheboygan 5272893, Wisconsin 5279468 53081
Stevens Point 5274644, Wisconsin 5279468 54481
Sturgeon Bay 5274867, Wisconsin 5279468 54235-1495
Wausau 5278120, Wisconsin 5279468 54401
Site Public Contact
877-405-6866
West Bend 5278422, Wisconsin 5279468 53095
Site Public Contact
414-805-0505
Wisconsin Rapids 5279436, Wisconsin 5279468 54494
Site Public Contact
715-422-7718
Manatí 4566137, Puerto Rico 00674
Site Public Contact
787-621-4397
San Juan 4568127, Puerto Rico 00927
San Juan 4568127, Puerto Rico 00927
San Juan 4568127, Puerto Rico 00936
Site Public Contact
787-763-1296
More Details
- Status
- Recruiting
- Sponsor
- Alliance for Clinical Trials in Oncology
Detailed Description
The primary and secondary objectives of the study: PRIMARY OBJECTIVES: I. To evaluate whether 6 months of combined neoadjuvant (neo)/adjuvant HER2 blockade results in a non-inferior recurrence-free survival (RFS) compared to 12 months of combined neo/adjuvant HER2 blockade, in patients with early stage HER2+ breast cancer who achieve pCR after neoadjuvant chemotherapy with HER2 blockade. II. To compare the Functional Assessment of Cancer Therapy-Breast (FACT-B) total score at 12 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life) SECONDARY OBJECTIVES: I. Secondary objectives are to evaluate whether 6 months compared to 12 months results in differences for the following: Ia. Grade 3 or higher adverse event (AE) rates; Ib. Overall survival (OS); Ic. Locoregional recurrence (LRR, both isolated LRR as first events, and LRR events simultaneous with distant metastasis [DM]) incidence; Id. RFS for key subgroups: baseline stage, hormone receptor (HR) status, neoadjuvant chemotherapy backbone, and dual versus single HER2 blockade in the adjuvant setting; Ie. Time to central nervous system (CNS) recurrence (both isolated CNS recurrence as first events, and CNS recurrence events simultaneous with distant metastasis and/or LRR). II. To compare the FACT-B total score at 18 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life) III. To compare side effect bother as measured by the Functional Assessment of Cancer Therapy General Population 5 (FACT GP5) item at 12 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life) IV. To compare specific patient-reported symptomatic adverse events (i.e. diarrhea, constipation, fatigue, and rash) as measured by the Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE) at 12 months between patients randomized to receive 6 months versus 12 months of combined neo/adjuvant HER2 blockade. (Quality of life) QUALITY OF LIFE EXPLORATORY OBJECTIVES: I. To examine the different FACT-B subscales at all other evaluable time points. II. To examine heterogeneity of treatment effects within subgroups defined by subcutaneous versus intravenous treatment delivery. OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients receive trastuzumab intravenously (IV) or subcutaneously (SC) on day 1 of each cycle. Patients may also receive pertuzumab IV or SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo echocardiography (ECHO) or multigated acquisition (MUGA) as well as mammography, ultrasound, or magnetic resonance imaging (MRI) throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial. ARM 2: Patients receive trastuzumab IV or SC on day 1 of each cycle. Patients may also receive pertuzumab IV or SC, at the discretion of the treating investigator, on day 1 of each cycle. Cycles repeat every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo ECHO or MUGA as well as mammography, ultrasound, or MRI throughout the trial. Patients may also optionally undergo blood and tissue sample collection throughout the trial. After completion of study treatment, patients are followed up every 6 months for 5 years after registration or until recurrence and then annually for a total of 10 years after registration.